Trametinib (CED0002166)

Trametinib belongs to the pyridopyrimidines, a class of organoheterocyclic compounds within the organic compounds. With an average molecular weight of 615.39 g/mol, Trametinib is a heavy molecule with the chemical formula C26H23FIN5O4. It is found in or released from two recorded sources: electrical and electronic equipment, specifically electric hearing aids, and healthcare, pharmaceuticals, and veterinary products, where it is categorized as an antineoplastic agent. The recorded exposure route for this compound is oral. At the molecular level, Trametinib acts on two recorded protein targets as an inhibitor of dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) and dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2). Regarding health effects, the compound is used as a treatment for melanoma (PMC13053802, PMC4554797, PMC5157796). It is also associated with rash (PMC10519171, PMC5157796), alopecia (PMC5157796), thrombosis (PMC10519171), and squamous cell carcinoma (PMC5157796).